Erbitux (cetuximab) is an antibody pharmaceutical. Cetuximab was first approved as Erbitux on 2004-02-12. It is used to treat squamous cell carcinoma in the USA. It has been approved in Europe to treat colorectal neoplasms and head and neck neoplasms. The pharmaceutical is active against epidermal growth factor receptor.
|Indication||colorectal neoplasms, head and neck neoplasms, squamous cell carcinoma|
|Drug Class||Monoclonal antibodies: chimeric, tumors as target|